This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Intellectual Property

Apr. 23, 2015

William G. Gaede III

McDermott Will & Emery LLP Menlo Park Patent


Last year, Gaede knocked down a patent-protected monopoly on a test that determines risk of women getting breast or ovarian cancer.


The test, developed in the early 1990s by Myriad Genetics Inc., sees whether women carry mutated BRCA1 or BRCA2 genes, which increase their risk for certain cancers.


It became highly publicized two years ago when Angelina Jolie wrote an essay in the New York Times, explaining she would have her breasts and ovaries removed ...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up